PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.